Anti-Cancer Monoclonal Antibodies Market to Reach $95.99
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The
Source: globenewswire.com
📰 Solid Tumor News
Page 2 - Solid Tumor News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Solid Tumor. Real-time updates on events, politics, business and more.
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
19.01.2024 - SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) - Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has entered into a definitive agreement to acquire select assets from Intermountain ... Seite 1
Paulj Diaz Intermountain Health System Intermountain Healthcare Precise Tumor Test Solid Tumor Precise Liquid
Source: wallstreet-online.de
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics - Myriad Genetics (NASDAQ:MYGN)
SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced it has entered into a definitive agreement to acquire select
Source: benzinga.com
Myriad Genetics to Acquire Precise Tumor, Precise Liquid
SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today...
Source: globenewswire.com
Dr O'Cearbhaill on Results With Ubamatamab Plus Cemiplimab in Recurrent Ovarian Cancer
Roisin E. O'Cearbhaill, MD, discusses key findings from a phase 1/2 dose escalation study of ubamatamab plus cemiplimab in recurrent ovarian cancer.
Roisine Ocearbhaill Gynecologic Medical Oncology Service Cellular Therapy Service Memorial Sloan Kettering Cancer Center Solid Tumor Onclive Tv
Source: onclive.com
Dragonfly Therapeutics Initiates Phase 1 1b Study of its IL-2 Immunotherapy in Patients with Advanced Solid Tumors
The company announces the first patient dosed in a Phase 1/1b clinical trial evaluating its novel IL-2 cytokine, DF6215, the seventh Dragonfly-developed drug ...
Prnewswire Dragonfly Therapeutics Inc Altre News Therapeutics Initiates Phase Advanced Solid Tumors Dragonfly Therapeutics Solid Tumor
Source: zazoom.it
Pidnarulex by Senhwa Biosciences for Solid Tumor: Likelihood of Approval
Pidnarulex is under clinical development by Senhwa Biosciences and currently in Phase I for Solid Tumor.
T Ai Pei Senhwa Biosciences Globaldata Pharmaceutical Intelligence Center Solid Tumor Phase Transition Success Rate Model New Taipei City
Source: pharmaceutical-technology.com
Oncology KRAS-targeting therapy market to exceed $4 billion by 2029
Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are common in solid tumors, including lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
United Kingdom Amgen Lumakras Biswajit Podder Mirati Therapeutics Revolution Medicines Bio Developments
Source: biopharma-reporter.com
NGS application development pipeline for Biomek NGeniuS
Beckman Coulter Life Sciences recently announced a collaboration agreement with Pillar Biosciences to forward NGS
Biomek Ngeniu Randy Pritchard Beckman Coulter Life Sciences Library Preparation System Industry News Pillar Biosciences
Source: selectscience.net
Cancer Immunity Cycle Could Inform Development of Novel Immune Therapies in RCC
Further understanding of the cancer immunity cycle could drive the development of novel immune therapies for patients with renal cell carcinoma.
United States Michaelb Atkins Vivek Narayan Eric Jonasch Katy Beckermann International Kidney Cancer Symposium
Source: onclive.com